Total revenue for 2025 was $65.3 million, a 19.9% increase from $54.4 million in 2024. Net loss for 2025 was $19.1 million, compared to a net loss of $16.2 million in 2024. Gross margin improved to 12.1% in 2025 from 7.9% in 2024, driven by a favorable shift toward higher-margin manufacturing and own-branded nutraceutical segments. The company continues to face substantial doubt regarding its ability to continue as a going concern due to recurring operating losses and negative operating cash flows. Operating expenses increased by 23.9% to $24.6 million, largely due to significant provisions for doubtful accounts and increased stock-based compensation.